Robles-Diáz G, Aceves G, Galván E
Instituto Nacional de la Nutrición, Salvador Zubirán.
Gac Med Mex. 1990 Mar-Apr;126(2):78-82; discussion 82-3.
Antigen CA 19-9 was measured in the serum of a group of 16 patients with pancreatic cancer, in 19 patients with non-pancreatic gastrointestinal malignancies, and in 19 others with benign pancreatobiliary disease. The test showed a high sensitivity with a low specificity and a positive predictive value for diagnosis of pancreatic cancer when confronted with a group of controls that included both benign and malignant gastrointestinal disease. The low specificity was due to high CA 19-9 values in other gastrointestinal cancers, especially in carcinoma of the ampulla and the biliary tract. When the latter were added to the group of patients with pancreatic cancer, and the diagnostic accuracy of the test was re-evaluated, sensitivity, specificity and both positive and negative predictive values increased. Values of CA 19-9 over 100 U/ml are highly predictive of malignancy in patients with pancreato-biliary disease.
对一组16例胰腺癌患者、19例非胰腺胃肠道恶性肿瘤患者以及19例其他良性胰胆疾病患者的血清进行了CA 19-9抗原检测。面对一组包括良性和恶性胃肠道疾病的对照组时，该检测对胰腺癌诊断显示出高敏感性、低特异性和阳性预测值。低特异性是由于其他胃肠道癌症，尤其是壶腹癌和胆管癌中CA 19-9值较高。当将后者加入胰腺癌患者组并重新评估该检测的诊断准确性时，敏感性、特异性以及阳性和阴性预测值均有所提高。CA 19-9值超过100 U/ml对胰胆疾病患者的恶性肿瘤具有高度预测性。
